These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 15527218)

  • 21. Biological perspectives. Serotonin and norepinephrine reuptake inhibitors (SNRIs): venlafaxine and duloxetine.
    Lee SI; Keltner NL
    Perspect Psychiatr Care; 2006 May; 42(2):144-8. PubMed ID: 16677140
    [No Abstract]   [Full Text] [Related]  

  • 22. [Change in the point of view].
    Krankenpfl J; 2005; 43(1-3):23-4. PubMed ID: 15912818
    [No Abstract]   [Full Text] [Related]  

  • 23. Duloxetine in the treatment of social anxiety disorder.
    Crippa JA; Filho AS; Freitas MC; Zuardi AW
    J Clin Psychopharmacol; 2007 Jun; 27(3):310. PubMed ID: 17502786
    [No Abstract]   [Full Text] [Related]  

  • 24. Duloxetine-modulating effects of brain structure in major depressive disorder with panic disorder.
    Lai CH
    J Clin Psychopharmacol; 2010 Feb; 30(1):88-9. PubMed ID: 20075662
    [No Abstract]   [Full Text] [Related]  

  • 25. [Dual acting reuptake inhibitors in the treatment of depression and pain].
    Hajak G
    Dtsch Med Wochenschr; 2006 Dec; 131 Suppl 8():S280-3. PubMed ID: 17139587
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dose-response relationship of duloxetine in placebo-controlled clinical trials in patients with major depressive disorder.
    Bech P; Kajdasz DK; Porsdal V
    Psychopharmacology (Berl); 2006 Oct; 188(3):273-80. PubMed ID: 16960699
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical evidence for serotonin and norepinephrine reuptake inhibition of duloxetine.
    Trivedi MH; Desaiah D; Ossanna MJ; Pritchett YL; Brannan SK; Detke MJ
    Int Clin Psychopharmacol; 2008 May; 23(3):161-9. PubMed ID: 18408530
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Wine and drug evaluations: lessons on making comparisons of noninferiority.
    Allgulander C; Nutt D
    J Psychopharmacol; 2008 Jun; 22(4):341-2. PubMed ID: 18635714
    [No Abstract]   [Full Text] [Related]  

  • 29. Successful duloxetine use to prevent venlafaxine withdrawal symptoms.
    Hsiao MC; Liu CY
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Feb; 32(2):576. PubMed ID: 17889418
    [No Abstract]   [Full Text] [Related]  

  • 30. [Evidence-based recommendations for the treatment of fibromyalgia syndrome].
    Harten P; Genth E
    Z Rheumatol; 2010 Jul; 69(5):457-60. PubMed ID: 18836732
    [No Abstract]   [Full Text] [Related]  

  • 31. Physical symptoms comorbid with depression and the new antidepressant duloxetine.
    Bailey KP
    J Psychosoc Nurs Ment Health Serv; 2003 Dec; 41(12):13-8. PubMed ID: 14682027
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and tolerability of duloxetine in elderly patients with major depressive disorder: a pooled analysis of two placebo-controlled studies.
    Oakes TM; Katona C; Liu P; Robinson M; Raskin J; Greist JH
    Int Clin Psychopharmacol; 2013 Jan; 28(1):1-11. PubMed ID: 23138680
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Benefits and harms in clinical trials of duloxetine for treatment of major depressive disorder: comparison of clinical study reports, trial registries, and publications.
    Maund E; Tendal B; Hróbjartsson A; Jørgensen KJ; Lundh A; Schroll J; Gøtzsche PC
    BMJ; 2014 Jun; 348():g3510. PubMed ID: 24899650
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Duloxetine (Yentreve) in the general practice test: recommendation by the experts. Effective and tolerable therapy of symptoms in female stress incontinence].
    Krankenpfl J; 2005; 43(7-10):189-90. PubMed ID: 16515261
    [No Abstract]   [Full Text] [Related]  

  • 35. Efficacy and tolerability of duloxetine, a novel dual reuptake inhibitor, in the treatment of major depressive disorder.
    Schatzberg AF
    J Clin Psychiatry; 2003; 64 Suppl 13():30-7. PubMed ID: 14552654
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Successful phase III study with serotonin-noradrenaline reuptake inhibitor. Soon a drug to control stress incontinence].
    MMW Fortschr Med; 2004 Feb; 146(7):59. PubMed ID: 15347056
    [No Abstract]   [Full Text] [Related]  

  • 37. Duloxetine in major depressed patients resistant to SSRIs and/or venlafaxine.
    Pitchot W; Scantamburlo G; Ansseau M
    Psychiatr Danub; 2010 Nov; 22 Suppl 1():S106-7. PubMed ID: 21057413
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Escitalopram and duloxetine in the treatment of major depressive disorder: a pooled analysis of two trials.
    Lam RW; Andersen HF; Wade AG
    Int Clin Psychopharmacol; 2008 Jul; 23(4):181-7. PubMed ID: 18545055
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Duloxetine--three birds with one stone?
    Michel MC
    Int J Clin Pract; 2007 Aug; 61(8):1247-8. PubMed ID: 17627705
    [No Abstract]   [Full Text] [Related]  

  • 40. The treatment of urinary incontinence with Duloxetine.
    Basu M; Duckett J
    J Obstet Gynaecol; 2008 Feb; 28(2):166-9. PubMed ID: 18393011
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.